Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02756624 · ClinicalTrials.gov registry record · Phase 3

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

A Phase 3 study, sponsored by Nicox Ophthalmics.

Completed
Registry status
Phase 3
Development phase
516
Enrollment target

NCT02756624 is a Phase 3 study that has completed, run by Nicox Ophthalmics. The registered enrollment target is 516 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02756624, a Phase 3 study, has completed, sponsored by Nicox Ophthalmics.

COMPLETED
Registry status
Phase 3
Development phase
516 participants
Enrollment target

Study Summary

This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution

Interventions

  • DRUG AC-170 0.24%
  • DRUG AC-170 Vehicle

Trial Details

FieldValue
Enrollment Target 516 participants
Start Date 2016-04
Est. Completion 2016-08
Phase Phase 3

Sponsor

Nicox Ophthalmics

7 total trials

What the Registry Record Tells You About NCT02756624

The ClinicalTrials.gov registry entry for NCT02756624 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 516 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicox Ophthalmics, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which AC-170 0.24% is the first listed.

NCT02756624 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02756624 about?

NCT02756624 is a clinical study titled "A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution". This is study is evaluating the safety and tolerability of AC-170 Ophthalmic Solution

What is the current status of trial NCT02756624?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 516 participants. The study started on 2016-04. Estimated completion is 2016-08.

What interventions are being tested in trial NCT02756624?

The interventions under investigation include: AC-170 0.24% (DRUG), AC-170 Vehicle (DRUG).

Who is sponsoring clinical trial NCT02756624?

This trial is sponsored by Nicox Ophthalmics, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.